Larimar Therapeutics (LRMR) EBT (2016 - 2020)
Historic EBT for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' EBT rose 7254.66% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 3849.55%. This contributed to the annual value of -$45.4 million for FY2019, which is 2568.26% up from last year.
- Larimar Therapeutics' EBT amounted to -$3.6 million in Q1 2020, which was up 7254.66% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' EBT ranged from a high of -$3.6 million in Q1 2020 and a low of -$17.8 million during Q1 2016
- Its 5-year average for EBT is -$13.0 million, with a median of -$13.1 million in 2019.
- Per our database at Business Quant, Larimar Therapeutics' EBT tumbled by 3275.68% in 2016 and then skyrocketed by 7254.66% in 2020.
- Quarter analysis of 5 years shows Larimar Therapeutics' EBT stood at -$10.3 million in 2016, then decreased by 26.76% to -$13.1 million in 2017, then fell by 10.72% to -$14.5 million in 2018, then surged by 49.65% to -$7.3 million in 2019, then skyrocketed by 50.66% to -$3.6 million in 2020.
- Its EBT stands at -$3.6 million for Q1 2020, versus -$7.3 million for Q4 2019 and -$12.9 million for Q3 2019.